INVERSINE
LOE Approachingmecamylamine hydrochloride
NDAORALTABLETPriority Review
Approved
Mar 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
INVERSINE (mecamylamine hydrochloride) is clinical pharmacology mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. Approved for hypertension. First approved in 1956.
Drug data last refreshed 22h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVERSINE (mecamylamine hydrochloride) is an oral ganglionic blocking agent approved in 1956 for hypertension management. It reduces blood pressure through sympathetic nervous system inhibition with gradual onset (0.5–2 hours) and prolonged duration (6–12+ hours). The drug crosses the blood-brain and placental barriers and is excreted unchanged in urine with rate influenced by urinary pH.
LOE Approaching
As LOE approaches with minimal recent spending data, brand teams are likely in transition or maintenance mode with reduced headcount and focus on legacy patient retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a longlasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood…
Indications (1)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.